Previous Article | Next Article 
Infection and Immunity, November 1999, p. 5730-5735, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Interaction of Mycobacterium
tuberculosis-Induced Transforming Growth Factor
1 and
Interleukin-10
Catherine
Othieno,1
Christina S.
Hirsch,2
Beverly D.
Hamilton,2
Katalin
Wilkinson,2
Jerrold J.
Ellner,2 and
Zahra
Toossi2,3,*
Department of Medicine, Case Western Reserve
University and University Hospitals of
Cleveland,2 and Veterans Affairs Medical
Center,3 Cleveland, Ohio 44106, and
Makerere University, Kampala, Uganda1
Received 19 March 1999/Returned for modification 5 May
1999/Accepted 5 August 1999
 |
ABSTRACT |
Mycobacterium tuberculosis is associated with the
activation of cytokine circuits both at sites of active tuberculosis in vivo and in cultures of mononuclear cells stimulated by M. tuberculosis or its components in vitro. Interactive stimulatory
and/or inhibitory pathways are established between cytokines, which may
result in potentiation or attenuation of the effects of each molecule
on T-cell responses. Here we examined the interaction of transforming growth factor
1 (TGF-
1) and interleukin-10 (IL-10) in purified protein derivative (PPD)-stimulated human mononuclear cell cultures in
vitro. TGF-
1 induced monocyte IL-10 (but not tumor necrosis factor
alpha) production (by 70-fold, P < 0.02) and mRNA
expression in the absence but not in the presence of PPD. Both
exogenous recombinant (r) IL-10 and rTGF-
1 independently suppressed
the production of PPD-induced gamma interferon (IFN-
) in mononuclear cells from PPD skin test-positive individuals. Synergistic suppression of IFN-
in cultures containing both rTGF-
1 and rIL-10 was only seen when the responder cell population were peripheral blood mononuclear cells (PBMC) and not monocyte-depleted mononuclear cells
and when PBMC were pretreated with rTGF-
1 but not with rIL-10.
Suppression of PPD-induced IFN-
in PBMC containing both rTGF-
1 (1 ng/ml) and rIL-10 (100 pg/ml) was 1.5-fold higher (P < 0.05) than cultures containing TGF-
1 alone and 5.7-fold higher (P < 0.004) than cultures containing IL-10 alone.
Also, neutralization of endogenous TGF-
1 and IL-10 together enhanced
PPD-induced IFN-
in PBMC in a synergistic manner. Thus, TGF-
1 and
IL-10 together potentiate the downmodulatory effect on M. tuberculosis-induced T-cell production of IFN-
, and TGF-
1
alone enhances IL-10 production. At sites of active M. tuberculosis infection, these interactions may be conducive to
the suppression of mononuclear cell functions.
 |
INTRODUCTION |
Cytokines play important roles in
the regulation of host immune responses against intracellular
pathogens, including Mycobacterium tuberculosis, by
controlling the proliferation, differentiation, and effector functions
of antigen-specific immune cells. Further, through autocrine and
paracrine mechanisms, cytokines regulate the production and the
biological effects of one another, thus augmenting or diminishing
beneficiary or detrimental host responses towards infectious agents.
Active tuberculosis (TB) is associated with suppression of T-cell
responses (12) and enhanced production and/or activity of
immunosuppressive molecules such as transforming growth factor
1
(TGF-
1) and interleukin-10 (IL-10). TGF-
1 and IL-10 overlap with
each other in many of their biological effects, including T-cell
suppression, macrophage deactivation, modulation of proinflammatory cytokines, and interference with antigen-presenting-cell function (9, 23). In a study of TB patients from Karachi, Pakistan, neutralizing antibody to TGF-
1 normalized lymphocyte proliferation in response to purified protein derivative (PPD) and significantly increased PPD-induced production of gamma interferon (IFN-
) in the
peripheral blood mononuclear cells (PBMC) of patients with TB, but it
had no effect on the PBMC of healthy PPD-reactive household contacts
(HC) of patients (14). In addition, coculture with neutralizing antibody to IL-10 augmented T-cell proliferation to PPD in
TB patients but not their HC. In contrast, stimulation of PBMC with PPD
and the mycobacterial 30-kDa alpha antigen induced greater secretion of
TGF-
, but not IL-10, in patients than HC. In recent studies of
patients with active TB in Uganda, we have observed enhanced production
of both IL-10 and TGF-
1 in PPD-activated PBMC culture supernatants
from TB patients compared to healthy PPD skin test-reactive control
subjects (12a). Further, coculture of PBMC from TB patients
with neutralizing antibodies to either TGF-
1 or IL-10 significantly
increased PPD-induced production of IFN-
in TB patients. Whether
TGF-
1 and IL-10 synergize with one another or function independently
to enhance the suppression of the IFN-
response in TB patients,
however, is not known.
Recently, Maeda et al. showed that TGF-
enhanced production of IL-10
by peritoneal macrophages in both normal and tumor-bearing mice
(15). However, an interaction between TGF-
and IL-10 in human mononuclear cell systems has not been investigated. M. tuberculosis and its constituents are strong inducers of a variety
of cytokines by monocytes (25). In particular, TGF-
1 is
induced by M. tuberculosis (13), its PPD
(20), and its major cell wall lipoglycan, lipoarabinomannan (6). Further, TGF-
1 is present in human tuberculous
granulomas (22).
In this study, we investigated the effect of TGF-
1 on the production
of IL-10 and the interactions of these two cytokines on PPD-induced
production of IFN-
in vitro. We found that TGF-
1 specifically
upregulated the production of IL-10 by human monocytes and that
together TGF-
1 and IL-10 synergistically suppressed PPD-induced
IFN-
production in PBMC.
 |
MATERIALS AND METHODS |
Study subjects.
Twenty-two healthy volunteers were studied
after informed consent was obtained. Ten subjects were PPD skin test
positive, and twelve were PPD skin test negative. Among the
participants in this study, 40% of the PPD skin test-reactive and 50%
of the PPD skin test-nonreactive subjects were females. Subjects were drawn within 2 to 3 years of their PPD skin test examination.
Preparation of cells.
PBMC were prepared from whole
heparinized blood by sedimentation over Ficoll-Paque (Pharmacia,
Piscataway, N.J.) (4). To obtain monocytes (MN), PBMC were
suspended at 107/ml in complete RPMI (BioWhittaker,
Walkersville, Md.) containing penicillin (50 U/ml), streptomycin (50 µg/ml), L-glutamine (2 mM), and HEPES (15 mM) and then
incubated on plastic petri dishes (75 by 100 mm; Falcon Plastics,
Oxnard, Calif.) that were precoated with 1 ml of pooled human serum
(PHS) for 1 h at 37°C. To remove the nonadherent cells (NAC),
the plates were washed three times with prewarmed RPMI. The adherent
cell monolayers were then covered with cold phosphate-buffered saline
(PBS) solution (BioWhittaker) and incubated at 4°C for 20 min. The
adherent cells were gently scraped off the plates with a plastic
scrapper and centrifuged at 250 × g for 10 min, and
the resulting pellet was suspended at 106/ml in complete
Iscove modified Dulbecco medium (IMDM) (BioWhittaker) (2 mM
L-glutamine, 15 mM HEPES, penicillin [50 U/ml],
streptomycin [50 mg/ml]) containing 1% PHS. Cells obtained in this
manner were 90 to 94% peroxidase positive and 80 to 90% nonspecific
esterase positive and contained <1% granulocytes as determined by
Wright staining; these cells are referred to here as MN. The viability of MN as determined by exclusion of 0.2% trypan blue was >95% in all
experiments. NAC were centrifuged at 250 × g for 10 min, and the resulting cell pellet was resuspended at 2 × 106 cells/ml in complete IMDM containing 1% PHS. NAC were
shown to contain 1 to 2% MN by peroxidase staining.
Antigens, cytokines, and antibodies used.
PPD was purchased
from the Statens Serum Institute (Copenhagen, Denmark) and was used at
final concentrations of 5 and 20 µg/ml. Recombinant (r) TGF-
1,
neutralizing chicken anti-TGF-
1 antibody, and chicken immunoglobulin
Y were purchased from R&D Systems (Minneapolis, Minn.). rIL-10,
neutralizing rat anti-human IL-10 antibody (clone JES3-9D7), and rat
isotype control antibody were obtained from Pharmingen (San Diego,
Calif.). The endotoxin content of all reagents as assessed by a
chromogenic Limulus lysate assay (BioWhittaker) was <0.01
ng/mg of protein for PPD, the neutralizing antibodies, and isotype
control antibodies and <15.0 ng/mg of protein for rTGF-
1 and
rIL-10. To inactivate any residual lipopolysaccharide (LPS), polymyxin
B (Sigma) was added to all cultures at 1 µg/ml. In preliminary
experiments (n = 2), this concentration of polymyxin B
reduced cytokine production by 30 ng of LPS per ml; tumor necrosis factor alpha (TNF-
) was reduced from 2.2 and 4.4 ng/ml to 0.7 and
0.9 ng/ml, respectively, and IL-10 was abrogated from 170 to 200 to 0 pg.
Generation of cytokine-containing supernatants.
PBMC (2 × 106/ml/well) in complete IMDM containing 1% PHS was
incubated in 24-well tissue culture plates (Corning, Corning, N.Y.)
with or without PPD. Culture supernatants were collected at 24 and
72 h of culture and stored frozen at
70°C until measurement of
cytokine contents by enzyme-linked immunosorbent assay (ELISA). MN were
seeded into 24-well tissue culture plates (106/ml/well) and
preincubated for 24 h with or without rTGF-
1 (1 to 10 ng/ml)
prior to the addition of PPD. Aliquots of the culture supernatant were
collected at 24 and 72 h for assessment of cytokines by ELISA.
NAC diluted to 2 × 106 cells/ml in complete IMDM were
incubated in 24-well tissue culture plates (2 × 106
cells/well) with or without rIL-10 (10 to 1,000 pg/ml) and TGF-
1 (0.1 to 10 ng/ml) in the presence or absence of PPD. Culture
supernatants were collected at 72 h and stored at
70°C until
assessed for cytokine content.
Immunoassay for cytokines.
TNF-
immunoreactivity was
measured by using a pair of mouse monoclonal antibodies to TNF-
(Pharmingen) as the capture and detection antibodies. A standard curve
was generated by using rTNF-
(Genzyme, Cambridge, Mass.) over a
concentration range of 15.6 to 1,000 pg/ml. This assay is sensitive to
15.6 pg of TNF-
activity per ml. The IL-10 ELISA uses a pair of rat
anti-human IL-10 antibodies as coating and capping antibodies
(Pharmingen). A standard curve was generated by using rIL-10
(Pharmingen) over a concentration range of 15.6 to 1,000 pg/ml. This
assay is sensitive to 15.6 pg of IL-10 activity per ml. IFN-
immunoreactivity was assessed with a commercially available ELISA kit
(Endogen, Boston, Mass.) with a sensitivity to 6.5 pg/ml.
Isolation and analysis of RNA.
Total RNA was extracted from
MN or PBMC (5 × 106 to 10 × 106) by
the guanidium-cesium method as described previously (19). For Northern blot analysis, 5 to 10 µg of RNA was electrophoretically separated through a 1% agarose-2.2 M formaldehyde gel containing ethidium bromide (0.5 mg/ml), transferred to nylon membranes, and
cross-linked to the membranes by using UV light (Stratagene). Membranes
were preincubated for at least 5 h in 1% fatty-acid-free bovine
serum albumin (Sigma), 0.2 M sodium phosphate (pH 7.2), 3.75 M
formamide, 0.001 M EDTA, and 7% sodium dodecyl sulfate (SDS) prior to
hybridization with a buffer similar to the prehybridization solution
containing a cDNA probe for human IL-10 (a 760-bp
BglII-HindIII fragment from the IL-10 plasmid
from the American Type Culture Collection, Rockville, Md.) or a
riboprobe for human IFN-
. Both probes were 32P labeled
by random priming. Filters then were washed (1× SSC [0.15 M NaCl plus
0.015 M sodium citrate]-0.1% SDS at 55°C for 15 min) and exposed
to Kodak XAR-5 film at
70°C with intensifying screens. To assess
equal loading of RNA, each blot was stripped by treatment with 0.5×
SSC-0.1% SDS and 50% formamide (65°C for 30 min) and then reprobed
with a riboprobe for 18S rRNA (American Type Culture Collection).
Immunostaining for IL-10R.
PBMC were cultured in the absence
or presence of rTGF-
1 (1 and 10 ng/ml) for 1 or 24 h. PBMC were
then washed, resuspended in PBS, and divided into two tubes. One tube
received biotin-conjugated rIL-10 (1 µl) (R&D Systems). After 60 min
at 4°C, the PBMC were washed and received avidin-fluorescein
isothiocyanate (FITC) (30 min at 4°C). The second (control) tube
received avidin-FITC alone. PBMC were then analyzed by
fluorescence-activated cell sorting (FACS); IL-10 staining of cells
gated with characteristics of lymphocytes and MN were assessed separately.
Statistical analysis.
Data were analyzed by using the paired
t test. A P value of <0.05 was considered significant.
 |
RESULTS |
Production of IL-10 and TNF-
by TGF-
1-pretreated MN.
First, the effect of TGF-
1 on production of IL-10 and TNF-
by MN
in the presence or absence of PPD of M. tuberculosis was examined. MN (106/ml) were preincubated for 24 h in
complete IMDM alone or in medium containing rTCF-
1 (1, 10, and 20 ng/ml). Then, PPD (5 or 20 µg/ml) or medium was added to the cell
cultures. An aliquot (50 µl) of culture supernatant was collected
after 24 h for measurement of TNF-
, and the rest was collected
at 72 h for IL-10 assessment. In preliminary work these time
points were found to be optimal for the measurement of TNF-
and
IL-10 by ELISA. In cultures without PPD, preincubation with rTGF-
1
induced IL-10 production in a dose-dependent manner (Fig.
1A). After preincubation with 20 ng of
rTGF-
1 per ml, but not with 1 or 10 ng of rTGF-
1 per ml, significantly greater concentrations of IL-10 were present in MN
cultures than in MN cultures without TGF-
1 (340 ± 120 versus 4 ± 1 pg/ml) (P < 0.05). In the presence of PPD,
TGF-
1 showed a bimodal effect on IL-10 production (Fig. 1A). IL-10
concentrations were lower in cultures containing rTGF-
1 at 1 ng/ml
plus PPD compared to cultures containing PPD alone. With higher amounts of rTGF-
1 (10 or 20 ng/ml), an increase in PPD-induced IL-10 concentration was seen. However, concentrations of IL-10 in
PPD-activated MN cultures in the presence of rTGF-
1 (10 or 20 ng/ml)
were not significantly different from those in the absence of TGF-
1.
At all doses of TGF-
1, on the other hand, PPD-induced TNF-
levels were lower in wells with TGF-
1 than in the wells without it (Fig. 1B). Also, rTGF-
1 alone failed to induce the production of TNF-
in MN cultures. Therefore, the effect of TGF-
1 on production of
IL-10 by MN is selective and does not include the upregulation of
another monocyte cytokine, TNF-
.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of TGF- 1 on IL-10 and TNF- production by
MN. MN were cultured in the absence or presence of rTGF- 1 (1 to 20 ng/ml), without or with PPD (5 and 20 µg/ml). Culture supernatants
were assessed for IL-10 at 72 h (A) and TNF- at 24 h (B)
by ELISA. Data represent the mean ± the standard error of the
mean from 10 separate experiments.
|
|
To assess whether increased TGF-

1-induced IL-10 production was also
associated with increased expression of IL-10 mRNA, total
RNA was
extracted and analyzed by Northern blot analysis by using
the IL-10
cDNA probe. Consistent with the cytokine ELISA data,
TGF-

1 increased
IL-10 mRNA expression modestly in the absence
of PPD (Fig.
2). However, PPD-induced IL-10 expression
was unaffected
by TGF-

1.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Induction of IL-10 expression by TGF- 1. MN were
cultured in the presence of medium alone (lanes 1 and 4) or with
rTGF- 1 at 2 ng/ml (lanes 2 and 5) or 20 ng/ml (lanes 3 and 6). PPD
(10 µg/ml) was added to lanes 4 to 6. Total RNA was assessed for the
expression of IL-10 mRNA at 24 h by Northern analysis. A
representative experiment (from three) is shown.
|
|
Effect of TGF-
1 and IL-10 on PPD-induced IFN-
production.
Next, we examined the interaction of IL-10 and
TGF-
1 on PPD-induced T-cell production of IFN-
. In preliminary
experiments, PPD-induced IFN-
production in PBMC and NAC was found
to be optimal after 72 h of culture. NAC from PPD skin
test-positive individuals were pretreated with IMDM alone or with IMDM
containing rTGF-
1 (0.1, 1, or 10 ng/ml). After 24 h, PPD alone
(5 µg/ml) or PPD together with rIL-10 (1 to 1,000 pg/ml) was added to
the cultures. Supernatants were collected at 72 h after PPD
stimulation for the assessment of IFN-
immunoreactivity. The
concentrations of cytokines used in this study bracket those found in
M. tuberculosis antigen-stimulated PBMC cultures of TB
patients (12a, 14). Suppression of IFN-
in all culture
supernatants was calculated in comparison to cultures of PPD-induced
PBMC (or NAC). The IFN-
immunoreactivity in cultures of NAC with PPD
alone were assigned a 100% response and were not suppressed (0%
suppression). In NAC cultures, a dose-dependent suppression of IFN-
production was seen with either TGF-
1 or IL-10. IL-10 at 1 ng/ml
showed an equivalent potency in suppression of IFN-
compared to 10 ng of TGF-
1 per ml (Fig. 3). When the
two cytokines were present together, an additive, but not synergistic,
effect on suppression of PPD-induced IFN-
production in NAC was
observed. Further, even when NAC were precultured with rTGF-
1 or
medium, washed, and then received PPD and IL-10, the suppressive effect
of the two cytokines on IFN-
production was additive but not
synergistic (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of IL-10 and TGF- on PPD-induced IFN-
production by NAC. The NAC from PPD-reactive donors (n = 7) were precultured with rTGF- 1 (0.1 to 10 ng/ml) or medium for
24 h. Then, PPD (5 µg/ml) and rIL-10 (1 to 1,000 pg/ml) were
added to the cultures. Culture supernatants were assessed for IFN-
at 72 h by ELISA. The percent suppression of IFN- was
calculated by assigning the IFN- in cultures that received PPD alone
as the 100% response (0% suppression).
|
|
However, when PBMC were the responder population instead of NAC, a
synergism of the two cytokines (TGF-

1 and IL-10) in the
suppression
of PPD-induced IFN-

production was observed. In these
experiments,
PBMC were precultured with TGF-

1 (1 or 10 ng/ml)
or medium for
24 h, and then PPD (5 µg/ml) with or without IL-10
(100 pg/ml)
was added to cultures (Fig.
4A).
Pretreatment with
rTGF-

1 at 1 ng/ml, but not at 10 ng/ml, leads to a
synergistic
suppression of IFN-

production when IL-10 (100 pg/ml)
was added.
Suppression of IFN-

by rTGF-

1 (1 ng/ml) alone was at
30.9% (
P < 0.05), and in the presence of both
rTGF-

and rIL-10 (100 pg/ml)
increased to 46% (
P < 0.004). Suppression of IFN-

by IL-10 (100
pg/ml) alone was ca.
8% (not significantly different than cultures
with PPD alone).
Pretreatment with IL-10 did not result in synergistic
suppression of
IFN-

at any dose of TGF-

1 or IL-10 (data not
shown).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of IL-10 and TGF- 1 on PPD-induced IFN-
production by PBMC. PBMC were precultured with rTGF- 1 (1 or 10 ng/ml) or medium for 24 h. Then, PPD (5 µg/ml) alone or together
with rIL-10 (100 pg/ml) was added to the cultures. (A) Culture
supernatants were assessed for IFN- immunoreactivity at 72 h,
and the percentages of suppression of IFN- were calculated. (B) PBMC
were cultured with medium alone (lanes 1 and 6), PPD (5 µg/ml) alone
(lanes 2 and 7), PPD plus rTGF- 1 at 10 ng/ml (lanes 3 and 8), PPD
plus rIL-10 at 100 pg/ml (lanes 4 and 9), and PPD plus both rTGF- 1
(10 ng/ml) and rIL-10 (100 pg/ml) (lanes 5 and 10). Total PBMC RNA was
assessed for the expression of IFN- mRNA at 24 h (lanes 1 to 5)
and at 96 h (lanes 6 to 10) by Northern analysis.
|
|
In three experiments, the effect of TGF-

1 with or without IL-10 on
PPD-induced expression of IFN-

mRNA in PBMC was examined.
For this
purpose, PBMC were precultured with rTGF-

1 (10 ng/ml)
or in medium
alone for 2 h, and then PPD (5 µg/ml) with or without
rIL-10
(100 pg/ml) was added to the cultures. Total RNA was extracted
from
PBMC after 24 h and after 4 days (96 h) of culture and was
assessed for expression of IFN-

mRNA by Northern analysis. Figure
4B
is a representative blot. The suppressive effect of IL-10 alone
was
seen only in early (24-h) cultures, whereas that of TGF-

1
was
sustained (24 h and 4 days). At both time points (24 h and
4 days), the
IFN-

message was lowest in cultures containing both
TGF-

1 and
IL-10.
Effect of neutralization of endogenous TGF-
1 and IL-10 on
PPD-induced IFN-
production.
Next, we assessed the effects of
neutralization of endogenous IL-10, TGF-
1, or both on PPD-induced
IFN-
production. In several experiments we found that the endogenous
levels of TGF-
1 and IL-10 in PPD-induced PBMC cultures were 1 to 2 and 100 pg/ml, respectively (data not shown). PBMC from PPD-positive
donors were cultured in complete IMDM with or without PPD (5 µg/ml)
in the presence or absence of neutralizing antibodies to TGF-
1 (5 µg/ml), IL-10 (2 µg/ml), or both. In preliminary experiments, these
amounts of neutralizing antibodies were found to abrogate the
bioactivity of 5 ng of TGF-
1 per ml and the immunoreactivity of 300 pg of IL-10 per ml. Control experiments received the same amounts of respective isotype-matched control antibodies. Culture supernatants were collected at 72 h and assessed for IFN-
immunoreactivity. Coculture with neutralizing antibody to TGF-
1 or IL-10 led to an
increase in IFN-
production above that in untreated PBMC cultures (Fig. 5); however, these improvements
were not significantly different from PPD-induced IFN-
production.
When both antibodies were present, a synergistic effect on PPD-induced
IFN-
production was seen. PPD-induced IFN-
levels doubled in
cultures containing both neutralizing antibody to TGF-
1 and
neutralizing antibody to IL-10 (P < 0.03).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of endogenous IL-10 and TGF- 1 on PPD-induced
IFN- production by PBMC. PBMC from nine separate donors were
cultured with medium alone or with neutralizing antibody to TGF- 1 (5 µl), to IL-10 (2 µl), or to both cytokines. Control wells received
isotype control antibodies for TGF- 1 (CAb), IL-10 (CAb'), or both
(CAb plus CAb'). PPD (5 µg/ml) was added to all cultures. IFN-
immunoreactivity was assessed in culture supernatants at 72 h. The
percent increase in IFN- immunoreactivity compared to that of PPD
alone (100%) is shown.
|
|
Effect of TGF-
on the expression of IL-10R in PBMC.
It was
possible that the synergistic effect of TGF-
1 and IL-10 on the
suppression of IFN-
was secondary to upregulation of IL-10R
expression on T cells or MN by TGF-
. Therefore, in some experiments
(n = 4) we cultured PBMC in the absence or presence of
rTGF-
1 (1 and 10 ng/ml) for 1 and 24 h and then performed immunostaining for IL-10R. For this purpose, biotin-conjugated rIL-10
(R&D Systems) and avidin-FITC were used. Control experiments received
avidin-FITC alone. PBMC were then analyzed by FACS; IL-10 staining of
cells gated with the characteristics of lymphocytes and MN were
assessed separately. Table 1 shows the
IL-10 staining results of PBMC at 24 h. IL-10 staining was
observed on 77.9 ± 8.4% of the MN and was not affected by
TGF-
1. Lymphocytes cultured with medium alone were 11.1 ± 2.6% (mean ± the standard deviation) IL-10R positive, and
preincubation with TGF-
1 at 10 ng/ml increased the IL-10R reactivity
to 17.1 ± 3.9%. However, these differences were not significant.
No effect of TGF-
1 on IL-10R was observed at 1 h. Therefore, we
conclude that TGF-
1 did not enhance the expression of IL-10R on
mononuclear cells.
 |
DISCUSSION |
In humans, both TGF-
1 and IL-10 are predominantly the products
of activated monocytes/macrophages (2, 10). Importantly, the
immunomodulatory effects of these two cytokines overlap to a great
degree with each other; both TGF-
1 and IL-10 suppress T-cell
functions (1, 7) and deactivate macrophages (3). Findings from this study suggest that these two cytokines are synergistic in their inhibition of PPD-induced production of IFN-
in
mononuclear cells in PPD-sensitized subjects. Further, a moderate effect of TGF-
1 on the enhancement of production of IL-10 by MN was
shown. Thus, TGF-
1 both directly and indirectly (through induction
of IL-10) may be suppressive of T-cell functions and the deactivation
of macrophages in M. tuberculosis infection. However, the
contribution of these interactions to the host immune response during
TB and at sites of active M. tuberculosis infection is not
presently clear.
IL-10 is tightly regulated at the transcriptional level (10,
16). It has been shown that TNF-
upregulates LPS-induced IL-10
expression in mononuclear phagocytes (26) and that IL-10 downregulates its own transcription (10). Further, it has
been shown that TGF-
1 enhances the production of IL-10 by
macrophages in normal and tumor-bearing mice (15). In the
present study, we observed a specific enhancing effect of TGF-
1 on
the production of IL-10 by human MN. IL-10 levels increased by ca.
70-fold (from a mean of 4 to 340 pg/ml) (P < 0.05) in
MN cultures that contained significant amounts of rTGF-
1 (20 ng/ml).
This effect was transcriptional, since TGF-
1 also modestly increased
IL-10 mRNA in MN. However, in PPD-induced cultures, the effect of
TGF-
1 on IL-10 production, like its other biologic effects
(24), was bimodal; at lower concentrations TGF-
1
decreased, and at higher concentrations it increased IL-10 in MN
cultures. However, these modulations of IL-10 by TGF-
1 in the
presence of PPD were not significant. Since IL-10 downregulates its own
transcription, it is possible that PPD-induced IL-10 masked any
enhancing effect of TGF-
1 on IL-10 production in the MN cultures.
Interestingly, human alveolar macrophages are limited in the production
of TGF-
1 compared to blood MN, but not IL-10 (21). At
sites of M. tuberculosis infection, where newly recruited MN
constitute a sizable proportion of the mononuclear cells
(18), local TGF-
1 (22) may upregulate the production of IL-10 by lung mononuclear phagocytes, thus enhancing immunosuppressive circuits.
Further, we showed a synergistic effect of TGF-
1 and IL-10 on
M. tuberculosis-induced IFN-
production in PBMC (Fig. 4)
but not in nonadherent cells (Fig. 3). Previous studies have shown that
IL-10 synergizes with both IL-4 and TGF-
1 in the inhibition of
macrophage cytotoxicity (17). This synergistic inhibitory effect on IFN-
in PBMC was shown both when exogenous cytokines (rIL-10 and rTGF-
1) were added and when endogenous cytokines (both
IL-10 and TGF-
1) were neutralized. Whether the expression of this
synergistic effect is mediated by a cell type or cytokine present in
PBMC but not NAC (e.g., MN) needs to be investigated. Clearly, the
small (1 to 2%) contamination of NAC with MN allows optimal induction
of IFN-
in cultures. In NAC cultures the suppression of PPD-induced
IFN-
by either IL-10 or TGF-
1 follow independent dose responses,
suggesting separate modes of suppressing T-cell responses. However, the
conditions for the expression of synergistic suppression of PPD-induced
IFN-
production is not present in cultures of NAC alone but is
present in PBMC cultures. These data suggest that the synergistic
effect of the deactivating cytokines (IL-10 and TGF-
1) on T-cell
IFN-
production appears to involve an early event involving antigen
presentation by MN. In this regard, both TGF-
1 and IL-10 interfere
with antigen presentation by MN through the downregulation of class II
major histocompatibility complex molecules (5, 10). In
addition, IL-10 interferes with the expression of the macrophage
costimulatory functions (8, 11). Further, TGF-
1
interferes with both early and late activation events of T cells upon
stimulation (1). Therefore, it is possible that the
synergistic effect of TGF-
1 and IL-10 in downmodulation of
PPD-induced IFN-
in PBMC is mediated through a combined effect on
the components of the antigen-presenting-cell function of mononuclear
phagocytes leading to T-cell activation.
However, it was also possible that the synergistic inhibition of
IFN-
by the deactivating cytokines was mediated through an
enhancement of the IL-10 response. Therefore, we examined the effect of
TGF-
1 on expression of IL-10R in PBMC in a limited number of
experiments. TGF-
1 did not significantly upregulate the expression
of IL-10R in MN or lymphocytes. Thus, the synergistic effect of IL-10
and TGF-
1 was not due to the upregulation of IL-10R. However, it is
still possible that cell signalling pathways are enhanced in a
synergistic manner in PBMC; this possibility needs to be investigated further.
In conclusion, the immunosuppressive activities of TGF-
1 and IL-10
may include both individual and combined components, depending on the
concentrations and kinetics of expression of each of these two
cytokines. At sites of active M. tuberculosis infection,
this interaction may result in a predominant suppressive effect on mononuclear cell function.
 |
ACKNOWLEDGMENTS |
This study was supported by grants from the National Institutes
of Health (AI45244 and AI18471) and a grant from the U.S. Department of
Veterans Affairs. C. Othieno was a recipient of a Fogarty grant award
from the National Institutes of Health during 1995 and 1996.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Infectious Diseases, Case Western Reserve University, Biomedical
Research Bldg., 10900 Euclid Ave., Cleveland, OH 44106-4984. Phone:
(216) 368-4843. Fax: (216) 368-2034. E-mail:
zxt2{at}po.cwru.edu.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Ahuja, S. S.,
F. Paliogianni,
H. Yamada,
J. E. Balow, and D. T. Boumpas.
1993.
Effect of transforming growth factor- on early and late activation events in human T cells.
J. Immunol.
150:3109-3118[Abstract].
|
| 2.
|
Assoian, R. K.,
B. E. Fleurdelys,
H. C. Stevenson,
P. J. Miller,
D. K. Madtes,
E. W. Raine,
R. Ross, and M. B. Sporn.
1987.
Expression and secretion of type B transforming growth factor by activated human macrophages.
Proc. Natl. Acad. Sci. USA
84:6020-6025[Abstract/Free Full Text].
|
| 3.
|
Bogdan, C.,
J. Paik,
Y. Vodovotz, and C. Nathan.
1992.
Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor and interleukin-10.
J. Biol. Chem.
267:23301-23308[Abstract/Free Full Text].
|
| 4.
|
Boyum, A.
1968.
Isolation of mononuclear cells and granulocytes from human blood.
Scand. J. Clin. Lab. Investig. Suppl.
97:9-29[Medline].
|
| 5.
|
Czarniecki, C. W.,
H. H. Chiu,
G. H. W. Wong,
S. M. McCabe, and M. A. Palladino.
1988.
Transforming growth factor- 1 modulates the expression of class II histocompatibility antigens on human cells.
J. Immunol.
140:4217-4224[Abstract].
|
| 6.
|
Dahl, K. E.,
H. Shiratsuchi,
B. Hamilton,
J. J. Ellner, and Z. Toossi.
1996.
Selective induction of transforming growth factor in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis.
Infect. Immun.
64:399-405[Abstract].
|
| 7.
|
Del Prete, G.,
M. De Carli,
F. Almerigogna,
M. G. Giudizi,
R. Biagiotti, and S. Romagnani.
1993.
Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production.
J. Immunol.
150:353-360[Abstract].
|
| 8.
|
de Waal-Malefyt, R.,
J. Haanen,
S. Hergen,
M. Roncarolo,
A. te Velde,
C. Figdor,
K. Johnson,
R. Kastelein,
H. Yssel, and J. E. de Vries.
1991.
Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.
J. Exp. Med.
174:915-924[Abstract/Free Full Text].
|
| 9.
|
de Waal-Malefyt, R.,
H. Yssel,
M. Roncarolo,
S. Hergen, and J. E. de Vries.
1992.
Interleukin-10.
Curr. Opin. Immunol.
4:314-320[Medline].
|
| 10.
|
de Waal-Malefyt, R.,
J. Abrams,
B. Bennett,
C. G. Figdor, and J. E. de Vries.
1991.
Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
J. Exp. Med.
174:1209-1220[Abstract/Free Full Text].
|
| 11.
|
Ding, L., and E. M. Shevach.
1992.
IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function.
J. Immunol.
148:3133-3139[Abstract].
|
| 12.
|
Ellner, J. J.
1997.
The human response in tuberculosis.
J. Infect. Dis.
176:1351-1359[Medline].
|
| 12a.
| Hirsch, C. S. Unpublished data.
|
| 13.
|
Hirsch, C. S.,
T. Yoneda,
J. J. Ellner,
L. E. Averill, and Z. Toossi.
1994.
Enhancement of intracellular growth of M. tuberculosis in human monocytes by transforming growth factor beta.
J. Infect. Dis.
170:1229-1237[Medline].
|
| 14.
|
Hirsch, C. S.,
R. Hussain,
Z. Toossi,
G. Dawood,
F. Shahid, and J. J. Ellner.
1996.
Cross-modulation by transforming growth factor in human tuberculosis: suppression of antigen-driven blastogenesis and interferon- production.
Proc. Natl. Acad. Sci. USA
93:3193-3198[Abstract/Free Full Text].
|
| 15.
|
Maeda, H.,
H. Kusahara,
Y. Ichimura,
M. Ohtsuki,
S. Kurakata, and A. Shiraishi.
1995.
TGF- enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice.
J. Immunol.
155:4926-4932[Abstract].
|
| 16.
|
Moore, K. W.,
A. O'Garra,
R. de Waal-Malefyt,
P. Vieira, and T. R. Mosmann.
1993.
Interleukin-10.
Annu. Rev. Immunol.
11:165-190[Medline].
|
| 17.
|
Oswald, I. P.,
R. T. Gazzinelli,
A. Sher, and S. L. James.
1992.
IL-10 synergizes with IL-4 and transforming growth factor- to inhibit macrophage cytotoxic activity.
J. Immunol.
148:3578-3582[Abstract].
|
| 18.
|
Shwander, S. K.,
E. Sada,
M. Torres,
D. Escobedo,
J. G. Sierra,
S. Alt, and E. A. Rich.
1996.
T lymphocytic and immature macrophage alveolitis in active pulmonary tuberculosis.
J. Infect. Dis.
173:1267-1272[Medline].
|
| 19.
|
Toossi, Z.,
J. P. Lapurga,
R. J. Ondash,
J. R. Sedor, and J. J. Ellner.
1990.
Expression of functional interleukin-2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis.
J. Clin. Investig.
85:1777-1784.
|
| 20.
|
Toossi, Z.,
T. Young,
L. E. Averill,
B. D. Hamilton,
H. Shiratsuchi, and J. J. Ellner.
1995.
Induction of transforming growth factor 1 by purified protein derivative of Mycobacterium tuberculosis.
Infect. Immun.
63:224-228[Abstract].
|
| 21.
|
Toossi, Z.,
C. S. Hirsch,
B. D. Hamilton,
C. K. Knuth,
M. A. Friedlander, and E. A. Rich.
1996.
Decreased production of transforming growth factor 1 (TGF- 1) in human alveolar macrophages.
J. Immunol.
156:3461-3468[Abstract].
|
| 22.
|
Toossi, Z.,
P. Gogate,
H. Shiratsuchi,
T. Young, and J. J. Ellner.
1995.
Enhanced production of transforming growth factor- (TGF- ) by blood monocytes from patients with active tuberculosis and presence of TGF- in tuberculous granulomatous lung lesions.
J. Immunol.
54:465-473.
|
| 23.
|
Wahl, S. M.
1992.
Transforming growth factor beta: a cause and a cure.
J. Clin. Immunol.
2:61-71.
|
| 24.
|
Wahl, S. M.,
N. McCartney-Francism,
J. B. Allen,
E. B. Dougherty, and S. F. Dougherty.
1990.
Macrophage production of TGF- and regulation of TGF- .
Ann. N. Y. Acad. Sci.
593:188-196[Medline].
|
| 25.
|
Wallis, R. S., and J. J. Ellner.
1994.
Cytokines and tuberculosis.
J. Leukoc. Biol.
55:676-681[Abstract].
|
| 26.
|
Wanidworanun, C., and W. Strober.
1993.
Predominant role of tumor necrosis factor- in human monocyte IL-10 synthesis.
J. Immunol.
151:6853-6861[Abstract].
|
Infection and Immunity, November 1999, p. 5730-5735, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Almeida, A. S., Lago, P. M., Boechat, N., Huard, R. C., Lazzarini, L. C. O., Santos, A. R., Nociari, M., Zhu, H., Perez-Sweeney, B. M., Bang, H., Ni, Q., Huang, J., Gibson, A. L., Flores, V. C., Pecanha, L. R., Kritski, A. L., Lapa e Silva, J. R., Ho, J. L.
(2009). Tuberculosis Is Associated with a Down-Modulatory Lung Immune Response That Impairs Th1-Type Immunity. J. Immunol.
183: 718-731
[Abstract]
[Full Text]
-
Samuel, L. P., Song, C.-H., Wei, J., Roberts, E. A., Dahl, J. L., Barry, C. E. III, Jo, E.-K., Friedman, R. L.
(2007). Expression, production and release of the Eis protein by Mycobacterium tuberculosis during infection of macrophages and its effect on cytokine secretion. Microbiology
153: 529-540
[Abstract]
[Full Text]
-
BROWN, M., MIIRO, G., NKURUNZIZA, P., WATERA, C., QUIGLEY, M. A., DUNNE, D. W., WHITWORTH, J. A. G., ELLIOTT, A. M.
(2006). SCHISTOSOMA MANSONI, NEMATODE INFECTIONS, AND PROGRESSION TO ACTIVE TUBERCULOSIS AMONG HIV-1-INFECTED UGANDANS.. Am J Trop Med Hyg
74: 819-825
[Abstract]
[Full Text]
-
Guyot-Revol, V., Innes, J. A., Hackforth, S., Hinks, T., Lalvani, A.
(2006). Regulatory T Cells Are Expanded in Blood and Disease Sites in Patients with Tuberculosis. Am. J. Respir. Crit. Care Med.
173: 803-810
[Abstract]
[Full Text]
-
Tanaka, N., Hoshino, Y., Gold, J., Hoshino, S., Martiniuk, F., Kurata, T., Pine, R., Levy, D., Rom, W. N., Weiden, M.
(2005). Interleukin-10 Induces Inhibitory C/EBP{beta} through STAT-3 and Represses HIV-1 Transcription in Macrophages. Am. J. Respir. Cell Mol. Bio.
33: 406-411
[Abstract]
[Full Text]
-
Birdsall, H. H., Porter, W. J., Trial, J., Rossen, R. D.
(2005). Monocytes Stimulated by 110-kDa Fibronectin Fragments Suppress Proliferation of Anti-CD3-Activated T Cells. J. Immunol.
175: 3347-3353
[Abstract]
[Full Text]
-
Andersson, A. K., Chaduvula, M., Atkinson, S. E., Khanolkar-Young, S., Jain, S., Suneetha, L., Suneetha, S., Lockwood, D. N. J.
(2005). Effects of Prednisolone Treatment on Cytokine Expression in Patients with Leprosy Type 1 Reactions. Infect. Immun.
73: 3725-3733
[Abstract]
[Full Text]
-
Bonecini-Almeida, M. G., Ho, J. L., Boechat, N., Huard, R. C., Chitale, S., Doo, H., Geng, J., Rego, L., Lazzarini, L. C. O., Kritski, A. L., Johnson, W. D. Jr., McCaffrey, T. A., Silva, J. R. L. e
(2004). Down-Modulation of Lung Immune Responses by Interleukin-10 and Transforming Growth Factor {beta} (TGF-{beta}) and Analysis of TGF-{beta} Receptors I and II in Active Tuberculosis. Infect. Immun.
72: 2628-2634
[Abstract]
[Full Text]
-
Khalifeh, M. S., Stabel, J. R.
(2004). Effects of Gamma Interferon, Interleukin-10, and Transforming Growth Factor {beta} on the Survival of Mycobacterium avium subsp. paratuberculosis in Monocyte-Derived Macrophages from Naturally Infected Cattle. Infect. Immun.
72: 1974-1982
[Abstract]
[Full Text]
-
Huard, R. C., Chitale, S., Leung, M., Lazzarini, L. C. O., Zhu, H., Shashkina, E., Laal, S., Conde, M. B., Kritski, A. L., Belisle, J. T., Kreiswirth, B. N., Lapa e Silva, J. R., Ho, J. L.
(2003). The Mycobacterium tuberculosis Complex-Restricted Gene cfp32 Encodes an Expressed Protein That Is Detectable in Tuberculosis Patients and Is Positively Correlated with Pulmonary Interleukin-10. Infect. Immun.
71: 6871-6883
[Abstract]
[Full Text]
-
Feng, C. G., Kullberg, M. C., Jankovic, D., Cheever, A. W., Caspar, P., Coffman, R. L., Sher, A.
(2002). Transgenic Mice Expressing Human Interleukin-10 in the Antigen-Presenting Cell Compartment Show Increased Susceptibility to Infection with Mycobacterium avium Associated with Decreased Macrophage Effector Function and Apoptosis. Infect. Immun.
70: 6672-6679
[Abstract]
[Full Text]
-
Bacellar, O., Lessa, H., Schriefer, A., Machado, P., Ribeiro de Jesus, A., Dutra, W. O., Gollob, K. J., Carvalho, E. M.
(2002). Up-Regulation of Th1-Type Responses in Mucosal Leishmaniasis Patients. Infect. Immun.
70: 6734-6740
[Abstract]
[Full Text]
-
van Crevel, R., Ottenhoff, T. H. M., van der Meer, J. W. M.
(2002). Innate Immunity to Mycobacterium tuberculosis. Clin. Microbiol. Rev.
15: 294-309
[Abstract]
[Full Text]
-
Wigginton, J. E., Kirschner, D.
(2001). A Model to Predict Cell-Mediated Immune Regulatory Mechanisms During Human Infection with Mycobacterium tuberculosis. J. Immunol.
166: 1951-1967
[Abstract]
[Full Text]